Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis

被引:180
作者
McDonald, Jay R. [1 ,2 ]
Zeringue, Angelique L. [1 ,2 ]
Caplan, Liron [4 ,5 ]
Ranganathan, Prabha [2 ]
Xian, Hong [1 ,2 ]
Burroughs, Thomas E. [3 ]
Fraser, Victoria J. [2 ]
Cunningham, Fran [6 ]
Eisen, Seth A. [1 ,2 ]
机构
[1] St Louis Vet Affairs Med Ctr, St Louis, MO 63106 USA
[2] Washington Univ, St Louis, MO USA
[3] St Louis Univ, St Louis, MO 63103 USA
[4] Univ Colorado, Hlth Sci Ctr, Denver, CO USA
[5] Denver Vet Affairs Med Ctr, Denver, CO USA
[6] Vet Affairs Pharm Benefits Management, Hines, IL USA
基金
美国国家卫生研究院;
关键词
ADVERSE DRUG-REACTIONS; UNITED-STATES; INFECTION; AGREEMENT;
D O I
10.1086/598331
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Herpes zoster occurs more commonly in patients taking immunosuppressive medications, although the risk associated with different medications is poorly understood. Methods. We conducted a retrospective cohort study involving 20,357 patients who were followed in the Veterans Affairs healthcare system and treated for rheumatoid arthritis from October 1998 through June 2005. Cox proportional hazards regression was used to determine risk factors for herpes zoster and herpes zoster-free survival. Chart review was performed to validate the diagnosis of herpes zoster. Results. The incidence of herpes zoster was 9.96 episodes per 1000 patient-years. In time-to-event analysis, patients receiving medications used to treat mild rheumatoid arthritis were less likely to have an episode of herpes zoster than patients receiving medications used to treat moderate and severe rheumatoid arthritis (P < .001). Independent risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate and severe rheumatoid arthritis, malignancy, chronic lung disease, renal failure, and liver disease. Among patients receiving tumor necrosis factor-alpha antagonists, etanercept (hazard ratio, 0.62) and adalimumab (hazard ratio, 0.53) were associated with a lower risk of herpes zoster. There was excellent agreement between the International Classification of Diseases, Version 9, Clinical Modification diagnosis of herpes zoster and diagnosis by chart review (kappa = 0.92). Conclusions. Risk factors for herpes zoster included older age, prednisone use, medications used to treat moderate and severe rheumatoid arthritis, and several comorbid medical conditions. These results demonstrate that the Department of Veterans Affairs' national administrative databases can be used to study rare adverse drug events.
引用
收藏
页码:1364 / 1371
页数:8
相关论文
共 32 条
[1]   Aging, immunity, and the varicella-zoster virus [J].
Arvin, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (22) :2266-2267
[2]  
BACIU A, 2007, FUTURE DRUG SAFETY P
[3]   HERPES-ZOSTER AND HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BUCHBINDER, SP ;
KATZ, MH ;
HESSOL, NA ;
LIU, JY ;
OMALLEY, PM ;
UNDERWOOD, R ;
HOLMBERG, SD .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (05) :1153-1156
[4]   Characteristics of patients with herpes zoster on presentation to practitioners in France [J].
Chidiac, C ;
Bruxelle, J ;
Daures, JP ;
Xuan, TH ;
Morel, P ;
Leplège, A ;
El Hasnaoui, A ;
de Labareyre, C .
CLINICAL INFECTIOUS DISEASES, 2001, 33 (01) :62-69
[5]   THE INCIDENCE OF HERPES-ZOSTER [J].
DONAHUE, JG ;
CHOO, PW ;
MANSON, JE ;
PLATT, R .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (15) :1605-1609
[6]   Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study [J].
Doran, MF ;
Crowson, CS ;
Pond, GR ;
O'Fallon, WM ;
Gabriel, SE .
ARTHRITIS AND RHEUMATISM, 2002, 46 (09) :2287-2293
[7]   Comorbidity measures for use with administrative data [J].
Elixhauser, A ;
Steiner, C ;
Harris, DR ;
Coffey, RN .
MEDICAL CARE, 1998, 36 (01) :8-27
[8]   Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management [J].
Gardam, MA ;
Keystone, EC ;
Menzies, R ;
Manners, S ;
Skamene, E ;
Long, R ;
Vinh, DC .
LANCET INFECTIOUS DISEASES, 2003, 3 (03) :148-155
[9]   Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes [J].
Haider, Asifa S. ;
Cardinale, Irma R. ;
Whynot, Julia A. ;
Krueger, James G. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2007, 12 (01) :9-15
[10]  
HARPAZ R, 2008, MMWR RECOMM REP, V57, P779